Polypharmacy in Patients with Chronic Kidney Disease.

Ilse J Oosting Julia M T ColombijnLotte KaasenbroodSophie Liabeuf Solène M LavilleLotty HooftMichiel L Bots Marianne Christina Verhaar Robin W M Vernooij

Published in: Kidney360 (2024)

The prevalence of polypharmacy in patients with CKD was over 80%, and highest in patients with a kidney transplant and those receiving dialysis. No causes of heterogeneity were identified, indicating that polypharmacy is an issue for all patients with CKD. Polypharmacy is associated with worse clinical outcomes, lower QoL, and medication-related problems in patients with CKD.

Keyphrases

chronic kidney disease
adverse drug
end stage renal disease
mental health
risk factors
healthcare
single cell
emergency department
electronic health record
drug induced